Yan-Yan Li1,2, Hui Wang3, Xin-Xing Yang1, Hong-Yu Geng1, Ge Gong1,4, Hyun Jun Kim5, Yan-Hong Zhou1, Jing-Jing Wu6. 1. Department of Gerontology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 2. Institute of Clinical Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 3. Department of Cardiology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 4. Department of Gerontology, Nanjing General Hospital, Nanjing, China. 5. Department of Physiology, University of Cincinnati, Cincinnati, OH, United States. 6. Department of Nephrology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Abstract
BACKGROUND: Many studies suggest that the small ubiquitin-like modifier 4 (SUMO4) M55V gene polymorphism (rs237025) may be associated with an increased risk of type 2 diabetes mellitus (T2DM). However, due to other conflicting results, a clear consensus is lacking in the matter. OBJECTIVE AND METHODS: A meta-analysis consisting of 6,823 subjects from 10 studies was conducted to elucidate relationship between the SUMO4 M55V gene polymorphism and T2DM. Depending on the heterogeneity of the data, either a fixed or random-effects model would be used to assess the combined odds ratio (ORs) and their corresponding 95% confidence interval (CI). RESULTS: SUMO4 gene M55V polymorphism was significantly associated with T2DM in the whole population under allelic (OR: 1.18, 95% CI: 1.10-1.28, P = 1.63 × 10-5), recessive (OR: 1.59, 95% CI: 1.14-2.23, P = 0.006), dominant (OR: 0.815, 95% CI: 0.737-0.901, P = 6.89 × 10-5), homozygous (OR: 1.415, 95% CI: 1.170-1.710, P = 0.0003), heterozygous (OR: 1.191, 95% CI: 1.072-1.323, P = 0.001), and additive genetic models (OR: 1.184, 95% CI: 1.097-1.279, P = 1.63 × 10-5). In our subgroup analysis, a significant association was found again in the Chinese population, but not in Japanese or Iranian population. CONCLUSION: SUMO4 gene M55V polymorphism may correlate with increased T2DM risk. Chinese carriers of the V allele of the SUMO4 gene M55V polymorphism may be predisposed to developing T2DM.
BACKGROUND: Many studies suggest that the small ubiquitin-like modifier 4 (SUMO4) M55V gene polymorphism (rs237025) may be associated with an increased risk of type 2 diabetes mellitus (T2DM). However, due to other conflicting results, a clear consensus is lacking in the matter. OBJECTIVE AND METHODS: A meta-analysis consisting of 6,823 subjects from 10 studies was conducted to elucidate relationship between the SUMO4 M55V gene polymorphism and T2DM. Depending on the heterogeneity of the data, either a fixed or random-effects model would be used to assess the combined odds ratio (ORs) and their corresponding 95% confidence interval (CI). RESULTS: SUMO4 gene M55V polymorphism was significantly associated with T2DM in the whole population under allelic (OR: 1.18, 95% CI: 1.10-1.28, P = 1.63 × 10-5), recessive (OR: 1.59, 95% CI: 1.14-2.23, P = 0.006), dominant (OR: 0.815, 95% CI: 0.737-0.901, P = 6.89 × 10-5), homozygous (OR: 1.415, 95% CI: 1.170-1.710, P = 0.0003), heterozygous (OR: 1.191, 95% CI: 1.072-1.323, P = 0.001), and additive genetic models (OR: 1.184, 95% CI: 1.097-1.279, P = 1.63 × 10-5). In our subgroup analysis, a significant association was found again in the Chinese population, but not in Japanese or Iranian population. CONCLUSION: SUMO4 gene M55V polymorphism may correlate with increased T2DM risk. Chinese carriers of the V allele of the SUMO4 gene M55V polymorphism may be predisposed to developing T2DM.
Entities:
Keywords:
meta-analysis; polymorphism; rs237025; small ubiquitin-like modifier 4; type 2 diabetes mellitus
Authors: Linda L Manza; Simona G Codreanu; Sheryl L Stamer; Darrin L Smith; K Sam Wells; Richard L Roberts; Daniel C Liebler Journal: Chem Res Toxicol Date: 2004-12 Impact factor: 3.739
Authors: M Morigi; S Angioletti; B Imberti; R Donadelli; G Micheletti; M Figliuzzi; A Remuzzi; C Zoja; G Remuzzi Journal: J Clin Invest Date: 1998-05-01 Impact factor: 14.808
Authors: P Quehenberger; A Bierhaus; P Fasching; C Muellner; M Klevesath; M Hong; G Stier; M Sattler; E Schleicher; W Speiser; P P Nawroth Journal: Diabetes Date: 2000-09 Impact factor: 9.461
Authors: H Y Lin; S L Li; M L Yu; P J Hsiao; M C Hsieh; K D Lin; C L Wang; T N Wang; S J Shin Journal: J Endocrinol Invest Date: 2009-11-12 Impact factor: 4.256
Authors: Tomislav Kelava; Petra Turcic; Antonio Markotic; Ana Ostojic; Dino Sisl; Anna Mrzljak Journal: World J Gastroenterol Date: 2020-03-28 Impact factor: 5.742